Johnson & Johnson's VARIPULSE Pro achieves 100% acute procedural success in AF study
JNJ•Johnson & Johnson presented study results at APHRS 2026 showing successful procedures in all patients treated with VARIPULSE Pro; one serious safety event resolved without lasting effects. OMNYPULSE showed sustained rhythm control at 12 months, improved quality of life and fewer cardiovascular-related hospitalizations.
1. Study results
Johnson & Johnson presented results for VARIPULSE Pro and investigational OMNYPULSE in atrial fibrillation ablation studies at APHRS 2026 in Busan, South Korea. VARIPURE reported successful procedures across all patients treated with VARIPULSE Pro; one serious safety event resolved without lasting effects. OMNYPULSE showed sustained rhythm control at 12 months, improved quality of life and reduced cardiovascular-related hospitalizations, with all reported safety events resolving.
2. Market availability
VARIPULSE Pro is available in Europe, Japan and other Asia-Pacific and Latin American markets, but does not have U.S. approval.
